These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 26536427

  • 1. Eculizumab use in kidney transplantation.
    Johnson CK, Leca N.
    Curr Opin Organ Transplant; 2015 Dec; 20(6):643-51. PubMed ID: 26536427
    [Abstract] [Full Text] [Related]

  • 2. Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders.
    Wehling C, Amon O, Bommer M, Hoppe B, Kentouche K, Schalk G, Weimer R, Wiesener M, Hohenstein B, Tönshoff B, Büscher R, Fehrenbach H, Gök ÖN, Kirschfink M.
    Clin Exp Immunol; 2017 Feb; 187(2):304-315. PubMed ID: 27784126
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of Eculizumab Therapy for Atypical Hemolytic Uremic Syndrome Recurrence and Antibody-Mediated Rejection Progress After Renal Transplantation With Preformed Donor-Specific Antibodies: Case Report.
    Yamamoto T, Watarai Y, Futamura K, Okada M, Tsujita M, Hiramitsu T, Goto N, Narumi S, Takeda A, Kobayashi T.
    Transplant Proc; 2017 Feb; 49(1):159-162. PubMed ID: 28104125
    [Abstract] [Full Text] [Related]

  • 4. Eculizumab in renal transplantation.
    Legendre C, Sberro-Soussan R, Zuber J, Rabant M, Loupy A, Timsit MO, Anglicheau D.
    Transplant Rev (Orlando); 2013 Jul; 27(3):90-2. PubMed ID: 23747093
    [Abstract] [Full Text] [Related]

  • 5. [Recurrent atypical hemolytic uremic syndrome after renal transplantation: treatment with eculizumab].
    Latzke AB, Fernández P, Chiurchiu C, Sarmantano D, De Arteaga J, Douthat W, De la Fuente J.
    Medicina (B Aires); 2018 Jul; 78(2):119-122. PubMed ID: 29659362
    [Abstract] [Full Text] [Related]

  • 6. Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use.
    Wijnsma KL, Duineveld C, Wetzels JFM, van de Kar NCAJ.
    Pediatr Nephrol; 2019 Nov; 34(11):2261-2277. PubMed ID: 30402748
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Prophylactic eculizumab for kidney transplantation in a child with atypical hemolytic uremic syndrome due to complement factor H mutation.
    Ranch D, Crowther B, Arar M, Assanasen C.
    Pediatr Transplant; 2014 Sep; 18(6):E185-9. PubMed ID: 24931815
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies.
    Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V, French Study Group for aHUS/C3G.
    Nat Rev Nephrol; 2012 Nov; 8(11):643-57. PubMed ID: 23026949
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of eculizumab treatment after kidney transplantation in patients with atypical haemolytic uraemic syndrome.
    van den Brand JA, Verhave JC, Adang EM, Wetzels JF.
    Nephrol Dial Transplant; 2017 Jan 01; 32(suppl_1):i115-i122. PubMed ID: 28391343
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.